Goodwin

Kevin Walsh

Deals
6
Latest
Jun 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 6 deals
Deals by year
Kevin Walsh: deals by year03620252026 YTD: 6 M&A62026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Kevin Walsh was named on, most recent first
Jun 2026 Alloy Enterprises –Johnson ControlsAcquisitionLegal adviser to Alloy Enterprises (target)Announced–Manufacturing+2Johnson Controls acquisition of Alloy Enterprises
May 2026 Anagram Therapeutics ––StakeLegal adviser to Anagram Therapeutics (target)Announced–Biotech+2Stake in Anagram Therapeutics
May 2026 Perfuse Therapeutics –BayerAcquisitionLegal adviser to Perfuse Therapeutics (target)Announced300.0Biotech+2Bayer acquisition of Perfuse Therapeutics
May 2026 LimmaTech Biologics AG –Eli Lilly and CompanyAcquisitionLegal adviser to LimmaTech Biologics AG (target)Pending780.0BiotechEli Lilly and Company acquisition of LimmaTech Biologics AG
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to Ouro Medicines (target)Announced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Mar 2026 Pikavation SynnovationNovartisAcquisitionLegal adviser to Synnovation Therapeutics (seller)Announced2,000.0Biotech+2Novartis acquisition of Pikavation

Deals where Kevin Walsh is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.